Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.
Robinson
R P
RP
Central Research Division, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, USA. ralph_p_robinson@groton.pfizer.com
Laird
E R
ER
Blake
J F
JF
Bordner
J
J
Donahue
K M
KM
Lopresti-Morrow
L L
LL
Mitchell
P G
PG
Reese
M R
MR
Reeves
L M
LM
Stam
E J
EJ
Yocum
S A
SA
D044482:Benzeneacetamides; D017364:Collagenases / Q000737:chemistry; D015195:Drug Design; D006877:Hydroxamic Acids / Q000138:chemical synthesis* / Q000737:chemistry; D053509:Matrix Metalloproteinase 13; D061965:Matrix Metalloproteinase Inhibitors; D008958:Models, Molecular; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D011760:Pyrrolidinones / Q000138:chemical synthesis* / Q000737:chemistry; D013329:Structure-Activity Relationship
C410930:3-(4-(4-fluorophenyloxy)phenyl)-2-oxopyrrolidine-4-hydroxamic acid; D044482:Benzeneacetamides; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D011760:Pyrrolidinones; D017364:Collagenases; D053509:Matrix Metalloproteinase 13